To determine whether other cancer-related genes may correlate with Src and MEK1/2 inhibitor sensitivity, we analyzed our previously published mutational analysis of thyroid cancer cell lines and did not observe a correlation with other oncogenic mutations, including TERT promoter mutations or dasatinib off-targets [15]. The gene discussed is MAP2K1; the disease is cancer.